Skip to main content
OpenTrials

Clinical trial condition

Blood Platelet Disorders

Explore clinical trials studying Blood Platelet Disorders. Study availability and eligibility vary by location and protocol.

28 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Blood Platelet Disorders trial results

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

NCT03275454

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +15 more
Locations
  • Georgetown Lombardi Comprehensive Cancer Center Georgetown, District of Columbia, United States
  • Massachusetts General Hospital - Cancer Center Boston, Massachusetts, United States
  • University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center Pittsburgh, Pennsylvania, United States
  • Essen University Hospital Department of Hematology Essen, Germany
View Trial Details
Completed

Observational Study of Elizaria® in aHUS Patients

NCT04749810

Conditions
Anemia, Anemia, Hemolytic, Atypical Hemolytic Uremic Syndrome, +21 more
Locations
  • Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" of the Ministry of Health of the Russian Federation Kazan', Russia
  • Regional State Budgetary Healthcare Institution "Krasnoyarsk' Regional Clinical Center for Maternity and Childhood Protection" Krasnoyarsk, Russia
  • State budgetary healthcare institution of the city of Moscow "Children's City Clinical Hospital of St. Vladimir of the Healthcare Department of the City of Moscow" Moscow, Russia
  • Federal State Autonomous Educational Institution of Higher Education "First Moscow State Medical University n.a. I.M. Sechenov" of the Ministry of Health of the Russian Federation Moscow, Russia
View Trial Details
Completed

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP

NCT01971684

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Mattel Children's Hospital Los Angeles, California, United States
  • Children's Hospital of Oakland Oakland, California, United States
  • Children's Hospital of Orange County Orange, California, United States
View all 29 locations
View Trial Details
Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

NCT01787552

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +13 more
Locations
  • Novartis Investigative Site Camperdown, New South Wales, Australia
  • Novartis Investigative Site Woolloongabba, Queensland, Australia
  • Novartis Investigative Site Leuven, Belgium
  • Novartis Investigative Site Toronto, Ontario, Canada
View all 18 locations
View Trial Details
Completed

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site St. Petersburg, Florida, United States
  • GSK Investigational Site Brooklyn, New York, United States
  • GSK Investigational Site Salt Lake City, Utah, United States
View all 51 locations
View Trial Details
Completed

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

NCT01558739

Conditions
Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, +11 more
Locations
  • Novartis Investigative Site Cardiff, Wales, United Kingdom
  • Novartis Investigative Site Bournemouth, United Kingdom
  • Novartis Investigative Site East Yorkshire, United Kingdom
  • Novartis Investigative Site Edinburgh, United Kingdom
View Trial Details

Related conditions